Johnson & Johnson reported strong third-quarter growth across Pharmaceuticals and Medical Devices, with significant sales increases in key products and positive guidance for the remainder of 2021. Despite some challenges in Consumer Health and increased litigation expenses, the overall performance and managementâ€™s optimistic outlook are likely to boost investor confidence in the short term. 

[1]